Clinical trials: Rivaroxaban
Healthy
Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X. Bleeding events related to rivaroxaban are the consequence of physiopathologic, pharmacokinetic issues or poisoning.
- Trial name
- RICHAR (NCT02657512)
- Testing
- rivaroxaban, rivaroxaban and activated charcoal
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Complications; Arthroplasty
Evaluation of Wound Drainage After Knee or Hip Arthroplasty
To compare side effects and complications relating to use of warfarin or rivaroxaban, tolerance and/or toxicity of these two agents such as drop in hemoglobin post operatively, extent of bruising, quantity of wound drainage…
- Trial name
- NCT02054936
- Testing
- Rivaroxaban (Xarelto), Warfarin (Coumadin)
- Where
- United States
- Sponsor
- University of Michigan
Atrial Fibrillation (AF)
Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)
Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.
- Trial name
- NCT06779695
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Korea University Anam Hospital
Healthy
A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
The purpose of this study is to assess the use of 2 different Prothrombin Complex Concentrates (PCCs) on their ability to reverse (normalize) the pharmacodynamic effects of rivaroxaban in healthy adult volunteers.
- Trial name
- NCT01656330
- Testing
- Rivaroxaban 20 mg twice daily, Rivaroxaban 20 mg once daily, Profilnine SD
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Atrial Fibrillation (AF), VTE
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure…
- Trial name
- PAUSE 2 RCT (NCT06957366)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 920 people
- Sponsor
- McMaster University
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Deep Vein Thrombosis
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the…
- Trial name
- NCT01516840
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 29 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Bayer
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male…
- Trial name
- NCT02537405
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events.
- Trial name
- EARLYmyo-LVT (NCT03764241)
- Testing
- Rivaroxaban, Vitamin K Antagonist
- Where
- China
- Volunteers
- 280 people
- Sponsor
- RenJi Hospital
Atrial Fibrillation
Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study
The main objective of the study is to assess preferences of Non Valvular Atrial Fibrillation (NVAF) patients towards different options of an anticoagulation treatment.
- Trial name
- X-PRESS (NCT02876718)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Taiwan
- Volunteers
- 253 people
- Sponsor
- Bayer
Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Purpose of the Pilot Trial: To determine the feasibility of conducting a multicentre randomized open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent central venous catheter (CVC) associated…
- Conditions
- Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis, Cancer
- Trial name
- TRIM-Line (NCT03506815)
- Testing
- Rivaroxaban 10 MG
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Ottawa Hospital Research Institute
Differences in Laboratory Coagulation Parameters
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery.
- Trial name
- NCT00986635
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Prophylaxis of Venous Thromboembolism
PK of Rivaroxaban in Bariatric Patients - Extension
Aim of this clinical Trial is the assessment of rivaroxaban PK/PD parameters in patients 6-8 months after bariatric surgery
- Trial name
- NCT02832947
- Testing
- Rivaroxaban 10 mg
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S.
- Trial name
- NCT02769078
- Testing
- dabigatran, rivaroxaban, apixaban
- Volunteers
- 14,201 people
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke, Intracranial Hemorrhages
Novel Oral Anticoagulants in Stroke Patients
The present study will monitor and explore acute neurovascular emergencies in patients treated with NOACs compared to those under treatment with VKAs.
- Trial name
- NOACISP (NCT02353585)
- Where
- Switzerland
- Volunteers
- 1,050 people
- Sponsor
- University Hospital, Basel, Switzerland
Atrial Fibrillation
BAY59-7939 in Atrial Fibrillation Once Daily (OD)
This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD) effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in Japanese subjects with non-valvular atrial…
- Trial name
- NCT00973245
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Warfarin
- Where
- 11 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Bayer
Cerebral Venous Sinus Thrombosis
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis
Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to 20 mg rivaroxaban were…
- Trial name
- NCT06551402
- Testing
- Dabigatran Etexilate 150mg, Rivaroxaban 20 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Kafrelsheikh University
Atrial Fibrillation
Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
The purpose of this study is to evaluate the antiinflammatory effects of rivaroxaban compared with dabigatran in patients with atrial fibrillation.
- Trial name
- RIVAL-AF (NCT02331602)
- Testing
- Rivaroxaban, Dabigatran
- Where
- 16 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Yokohama City University Medical Center
Atrial Fibrillation
Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot
The proposed PAUSE-2 RCT study is the logical next step to the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study, which was completed on August 31, 2018.
- Trial name
- PAUSE2rctP (NCT04192552)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 3 sites in Canada
- Volunteers
- 201 people
- Sponsor
- McMaster University
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Phase I Study of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects.
- Trial name
- NCT07024160
- Testing
- MT1011
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.